Phase 2TerminatedINTERVENTIONAL
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
ClinicalTrials.gov · NCT06865677 · Registry updated: 2026-01-21
- Condition / research focus
- Recurrent Platinum Resistant Epithelial Ovarian Carcinoma; Recurrent Epithelial Endometrial Carcinoma; Recurrent Epithelial Cervical Carcinoma
- Sponsor
- National Cancer Institute (NCI)
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2025-06-09. Completion: 2025-07-01 (may be estimated). Results are posted in this registry.
Products and interventions (9)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Sacituzumab Govitecan (drug) — also listed as: Trodelvy
- EKG (diagnostic_test) — also listed as: Electrocardiogram
- Brain MRI (diagnostic_test) — also listed as: Brain magnetic resonance imaging
- CT scans (diagnostic_test) — also listed as: Computed tomography scans
- Tumor biopsy (procedure) — also listed as: Tumor bx
- Loperamide (drug) — also listed as: Immodium
- Octreotide (drug) — also listed as: Sandostatin, Bynfezia, Mycapssa
- Diphenoxylate/Atropine (drug) — also listed as: Lomotil
- Antiemetics (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site recruitment: Not reported